On the 25th of May 2018 the new regulation in EU law on data protection and privacy for all individuals within the European Union, GDPR, was implemented. In connection with this we updated our privacy policy. Please see the complete policy below.
Privacy policy
The Processing of Personal Data
Our objective and intention is that you will be able to feel safe and secure when you provide your personal information to us at Sandberg Development AB. All processing of personal data is based on the provisions and requirements of the European Union’s General Data Protection Regulation (GDPR).
Data Controller
Sandberg Development AB is the data controller, pursuant to the GDPR, for the processing of personal data held by the company that takes place. Sandberg Development AB is responsible for the processing of personal data that takes place via our website www.sandbergdevelopment.com.
When does the processing of personal data occur?
Sandberg Development AB processes your personal information when you:
· order publications
· sign up for our newsletter subscription service, or other similar services,
· look for an open position, register your interest in employment, or apply for employment with us,
· otherwise seek contact with us
Data registered
When individuals place orders or make registrations, their name, address, telephone number and e-mail address are registered. When representatives of a company place orders or make registrations the name of the company’s contact persons, their position and the department they are from, well as their address, telephone number and e-mail address to the workplace, are registered. In other situations, the data you have chosen to provide is registered. Sandberg Development AB’s seeks to avoid registering civil identification numbers (social security numbers) and sensitive personal data such as racial or ethnic origin, political opinions, religious or philosophical beliefs, membership in trade unions, health matters and sex life. If you do provide such information, for example, prior to a seminar that you have a food allergy/intolerance and want or want to avoid certain foods, we presume that you want the information to be registered with us.
The purpose of the processing of personal data
When you ask for our courses and seminars, or order publications or newsletters via our website, by telephone or mail, you become a customer of ours. The personal information you provide is registered in our customer database and is used for the processing of providing the services and products that have been ordered. The information may also be used for marketing purposes as well as for follow-ups.
When you look for an open position with us, submit an expression of interest regarding employment with us, or apply, participate in surveys and provide information for “benchmarking” or tell us you want to be considered by us, we use your personal information only for the purpose for which you provided it.
Disclosure of personal data to others
With orders and registrations, the information recorded in the customer database may be disclosed to third parties, in other words to individuals or companies outside of Sandberg Development AB, to the extent necessary to be able to administer the participation in a course or seminar, or to process and fulfill the order. This also applies when you look for an open position, submit an expression of interest regarding employment, or apply for a job with us, participate in surveys and provide information for “benchmarking,” or tell us you want to be contacted by us. In all of the above-mentioned situations, Sandberg Development AB is the “data controller” responsible for the personal data and the contractors Sandberg Development AB uses are the “data processors”. The data processors are obligated to comply with Sandberg Development AB’s instructions and are not entitled to disclose your personal information to any other parties or to use them for any purposes other than those encompassed within Sandberg Development AB’s instructions. The data processors are also required to take certain technical and organizational measures to protect your personal data.
Finally, personal data may also be disclosed in the event this is required by law, regulation or a decision of a governmental authority.
How long is the information retained?
We retain the personal data for as long as necessary in order for us to be able to fulfill our commitments, i.e. provide the service, product or training, invoices, deal with complaints or claims, etc. If you have consented to that your contact information will remain in our customer database for marketing purposes even after the customer relationship has ended, it will remain in the database until you tell us that you want the information deleted.
Contact
If you have any questions concerning the processing of personal data within Sandberg Development AB, please contact us here
Registry extracts and corrections
You are entitled to obtain, once a year without cost, information about the personal data concerning you that is being processed by Sandberg Development AB. In such case, make your request in writing to the Data Protection Officer (for the address, see above). If in your opinion some information about you is incorrect or misleading, you can contact the Data Protection Officer and make a written request for a change.
Identification of Visitors– cookies and logs
Our website uses “cookies.” As you may know, “cookies” are small text files that are stored on your computer and among other uses, they are used to saving individualized settings and make it possible to monitor what visitors do on the website. There are two different types of “cookies.” One is “session cookies,” which are used during the time the visitor is active on the website. These cookies are only stored temporarily on the visitor’s computer, and are deleted automatically when the user closes their web browser. The other is “persistent cookies.” These are used to tell the visitor what happened on the website since they last visited the site, and to be able to identify returning users and remember the information provided previously. The initial settings for most browsers are set to accept cookies. However, if you do not want cookies to be stored in your computer, you can set your browser to notify you when it receives a cookie. At that point you can decide for yourself if you want to accept it or not. Sandberg Development AB prepares statistics relating to the number of visits and visitors, number of times each individual page is read, which URLs the visitor is coming from, and which search engines and keywords are used to reach our website. The purpose of all this is to give us an understanding of how we can improve our site and your experience as a customer. In this way we collect information about the domain name, web browser and operating system, the time when you entered our website and if you came via a link, what link. This information is not to be disclosed to third parties.
Security
There is always a risk involved with the submitting of personal information via the Internet. No technology system is completely protected from intrusion. However, Sandberg Development AB has taken all reasonable technical security measures that are required in order to protect personal data against unauthorized access, alteration or destruction.
Malmö, 25 May 2018
Martin Jonsson
President/CEO of Sandberg Development AB
Camurus Annual Report for 2020 is now available at the company's website.
Read moreGranuldisk was selected as one of the finalists presented by Malmö Näringslivsgala, a business gala for companies located in Malmö, Sweden.
Read moreCamurus announced on December 10, 2020, that the ICC International Court of Arbitration has issued a partial award in the arbitration process between Camurus and Braeburn regarding the parties’ license agreement for the development and commercialization of CAM2038 in North America.
Read moreCamurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read moreGAIM launches their new website on the domain www.gaim.com
Read more"Good performances were seen across markets and we are on track to deliver on our revenue guidance."
Read moreISEC Monitoring Systems has received three substantial and strategically important orders during the last year, amounting to appr. 20 MSEK.
Read more”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read moreCamurus has completed a directed share issue of 2 million shares, raising proceeds of SEK 300 million.
Read morePositive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers with obesity.
Read moreThe improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and Australia.
Read more”The number of patients treated with Buvidal® increased by 90 percent in the quarter”
Read moreCamurus Annual Report for 2019 is now available at the company´s website.
Read moreCamurus announced today continued strong revenue growth driven by increasing demand for weekly and monthly Buvidal® for the treatment of opiod dependence in EU and Australia.
Read moreCamurus has published their Full year report 2019
Read moreThe directed share issue (which was completed on December 6, 2019) of approximately 3,7 million shares will raise proceeds of approximately 300 MSEK.
Read moreGRANULDISK has launched biodegradable granules, which eliminate the need for pre-washing, all while being kind to the environment.
Read moreAustralia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical Benefit Scheme (PBS).
Read moreISEC has launched three new products for better and safer surveillance of radioactive environments.
Read moreCamurus’ partner Braeburn have received a positive outcome in the US court proceedings which were initiated in April, 2019, regarding final approval for Brixadi (Buvidal® in the US) and the FDA is remanded to reconsider Braeburn’s application for final approval of Brixadi™ Monthly in the US.
Read moreThe FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-monthly octreotide subcutaneous depot for treatment of acromegaly.
Read moreStarting June 2019, all Sandberg Development's office and production facilities will be cleaned and washed with DIRO® water - completely without chemicals.
Read moreCamurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product.
Read moreNew positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl abuse, among other things, compared to other standard treatments as well as lower withdrawal and drug craving.
Read moreCamurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of the launch and marketing of Buvidal in Europe and Australia.
Read moreAimpoint has been awarded a large contract of USD 24 million from the U.S. Military for the FCS13-RE system for SAAB’s portable weapon system Carl-Gustaf (MAAWS) and to be used by the U.S. Army, U.S. Marine Corps and the U.S. Special Operations Command.
Read moreBased on Aimpoint's red dot sight for fire arms, the company has developed a commercial VR platform, GAIM, which is now spun off to a separate company.
Read moreIn 1959, Gunnar Sandberg established ElektroSandberg and lay the foundation for what we now know as Sandberg Development.
Read moreCamurus' has published their Full year report 2018.
Read moreAs of January 7 Mikael Samuelsson is the new CEO for GRANULDISK.
Read moreDuring the summer it was decided to spin off operations focused on the decontamination of fire rescue equipment from GRANULDISK into a separate company - RESCUE Intellitech.
Read moreIn November 2019 Mats Marklund took office as CEO for SWATAB.
Read moreCamurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead products Buvidal® Weekly and Buvidal® Monthly (CAM2038) for maintenance treatment of opioid dependence within a framework of medical, social and psychosocial support.
Read moreCamurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. Buvidal® is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents.
Read more“Following the positive CHMP opinion for Buvidal®, we have ramped up our commercial activities and are ready for launch in the first wave European markets”, Fredrik Tiberg, President and CEO, says in his CEO comments.
Read moreAF Bostäder in Lund will open two new laundry rooms at Vildanden, a student housing, where the students can wash with super-clean water in a chemical-free process.
Read moreSandberg Development has decided to spin-off and concentrate the business within the subsidiary GRANULDISK’s product area SOLO Rescue.
Read moreThe family owned investment company Sandberg Development invests in SWATAB (SCANDINAVIAN WATER TECHNOLOGY AB). The investment implies a growth venture with an upscaling of the organization and production, which will be built in Sandberg Development’s premises in Malmö.
Read moreOn the 25th of May 2018 the new regulation in EU law on data protection and privacy for all individuals within the European Union, GDPR, was implemented. In connection with this we updated our privacy policy. Please see the complete policy below.
Read moreSandberg Development invests SEK 30 million in the Malmö-based water recycling technology Company Orbital Systems.
Read moreIn the beginning of November reconstruction work started at our office facilites at Jägershillgatan 15 in Malmö.
Read moreAs part of our business concept - "Investing in innovations with growth in focus" - Sandberg Development has, during the summer, invested in an unlisted development Company, ISEC AB.
Read moreNew data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder.
Read moreOn April 18, 2017 the purchase deed was signed and Sandberg Development is now the owner of the property.
Read moreOne year after the reconstruction work started, the new production facilities were completed in March 2017.
Read moreIn March 2016 reconstruction and extension work started at our premises on Jägershillgatan 15 in Malmö. The first part of the reconstruction work involves the production facilities.
Read moreFrom 2015 Sandberg Development is a sponsor of Star for Life, an educational/motivational programme, the aim of which is to strengthen the self esteem of young people and to counter the spread of HIV/AIDS.
Read moreOn Thursday December 3, 2015, Camurus started its first day of trading on Nasdaq Stockholm. The share price increased considerably during the first day and Camurus is now the largest company in the biotechnology sector on Nasdaq Stockholm
Read moreCamurus announces initial public offering on Nasdaq Stockholm. The company plans a new shares issue to a value of SEK 500 million net - a market capitalization of appr. SEK 2 billion.
Read moreOn November 3, 2015, Sandberg Development received Mazars prize for sustainable business. Per Sandberg was present at the prize ceremony which took place in Malmö.
Read moreAs of August 25, 2015 Kent Bengtsson started working as CFO in Sandberg Development.
Read moreGRANULDISK recently moved into new facilities in Malmö. The history behind the large-scale investment is strong growth in Sweden and Europe and increased demand, not least from Asia and the Middle East. The company has recruited about ten new employees and expects to recruit more in the longer run.
Read moreIn the wake of an extensive branding process, GS Development is changing its name to Sandberg Development AB. This process was initiated to clarify its communications so that they reflect the group’s focus on world-class innovations.
Read more